Table 4.
Multivariate analysis for patients with T1-2N0 TNBC.
| Relapse-free survival | Overall survival | |||||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |||||
| VISTA on ICs | 0.044 | 0.024 | ||||||
| Negative | 1 | 1 | ||||||
| Positive | 0.462 (0.218–0.979) | 0.281 (0.093–0.848) | ||||||
| Age | 0.469 | 0.303 | ||||||
| < 50 years | 1 | 1 | ||||||
| ≥ 50 years | 1.328 (0.617–2.858) | 1.758 (0.601–5.147) | ||||||
| Tumor stage | 0.115 | 0.302 | ||||||
| T1 | 1 | 1 | ||||||
| T2 | 1.851 (0.861–3.982) | 1.764 (0.601–5.179) | ||||||
| Ki 67 | 0.409 | 0.966 | ||||||
| < 14% | 1 | 1 | ||||||
| ≥ 14% | 1.677 (0.492–5.717) | 1.034 (0.220–4.854) | ||||||
| Differentiation | 0.924 | 0.612 | ||||||
| Moderate+Well | 1 | 1 | ||||||
| Poor | 1.043 (0.436–5.717) | 1.399 (0.382–5.115) | ||||||
TNBC, triple-negative breast cancer; VISTA, V-domain Ig suppressor of T-cell activation; IC, immune cell; AJCC, American Joint Committee on Cancer; CI, confidence interval.